Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
- 5 November 2007
- Vol. 112 (1), 84-93
- https://doi.org/10.1002/cncr.23140
Abstract
BACKGROUND. Death receptors mediate both apoptosis and survival in cancer cells. The authors analyzed death receptor expression in metastatic ovarian carcinoma. METHODS. Viable tumor cells in ovarian carcinoma effusions (n = 95) were analyzed for DR4, DR5, Fas, TNFR1, and TNFR2 expression using flow cytometry. Results were analyzed for association with clinicopathologic parameters, chemotherapy response, and survival. RESULTS. DR4, DR5, and Fas were expressed by the majority of specimens, with less frequent expression of TNFR1 and TNFR2. DR4 (P = .005) and TNFR2 (P = .041) expression was higher in FIGO stage IV compared with stage III tumors. Effusions from patients who responded poorly to chemotherapy administered at disease recurrence had significantly higher DR4 (P = .006), DR5 (P = .01), and Fas (P = .001) expression. In univariate survival analysis, higher DR4 expression in viable cells correlated with poor overall (P = .0352) and progression‐free (P = .0411) survival. DR4 expression was found to be an independent predictor of overall (P = .008) and progression‐free (P = .003) survival. CONCLUSIONS. The authors have presented the first evidence of death receptor coexpression in ovarian carcinoma effusions. The association of death receptor expression in effusions with advanced stage, poor response to chemotherapy, and shorter survival suggests that these molecules are linked to an aggressive clinical course in metastatic ovarian carcinoma. Cancer 2008. © 2007 American Cancer Society.Keywords
This publication has 47 references indexed in Scilit:
- Flow cytometric immunphenotyping of epithelial cancer cells in effusions—Technical considerations and pitfallsCytometry Part B: Clinical Cytometry, 2007
- Drug Insight: cancer therapy strategies based on restoration of endogenous cell death mechanismsNature Clinical Practice Oncology, 2006
- TNF-α in Cancer Treatment: Molecular Insights, Antitumor Effects, and Clinical UtilityThe Oncologist, 2006
- Targeted Induction of Apoptosis in Cancer Management: The Emerging Role of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor Activating AgentsJournal of Clinical Oncology, 2005
- TRAIL Promotes the Survival and Proliferation of Primary Human Vascular Endothelial Cells by Activating the Akt and ERK PathwaysCirculation, 2003
- Fas engagement induces neurite growth through ERK activation and p35 upregulationNature, 2003
- Tumor necrosis factor signalingCell Death & Differentiation, 2003
- Targeting death and decoy receptors of the tumour-necrosis factor superfamilyNature Reviews Cancer, 2002
- Death and anti-death: tumour resistance to apoptosisNature Reviews Cancer, 2002
- Expressions of Fas ligand and other apoptosis-related genes and their prognostic significance in epithelial ovarian neoplasmsBritish Journal of Cancer, 2000